Sarah Gheuens
Chief Tech/Sci/R&D Officer chez AGIOS PHARMACEUTICALS, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Sarah Gheuens is currently the Director at Viridian Therapeutics, Inc. since 2023.
She is also the Chief Medical Officer and Head of Research & Development at Agios Pharmaceuticals, Inc. since 2019.
In terms of education, Dr. Gheuens holds a doctorate degree from Vrije Universiteit Brussel, a graduate degree from Harvard Medical School, and another doctorate degree from the University of Antwerp.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/03/2024 | 39 066 ( 0,07% ) | 1 M $ | 31/03/2024 | |
| 21/09/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Sarah Gheuens
| Sociétés | Poste | Début |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2021 |
| VIRIDIAN THERAPEUTICS, INC. | Director/Board Member | 25/09/2023 |
Formation de Sarah Gheuens
| Vrije Universiteit Brussel | Doctorate Degree |
| Harvard Medical School | Graduate Degree |
| University of Antwerp | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
